Angiographic Characteristics of CSC, PCV Patients and Thrombotic Bio-markers

Samsung Medical Center

Status: Unknown

Conditions: Polypoidal Choroidal Vasculopathy; Central Serous Chorioretinopathy

Treatments: Other: Blood sampling

Study type: Observational

Funder types: Other

Identifiers

NCT02815176

2016-02-109

Details and patient eligibility

About

Thrombotic biomarkers and angiographic characteristics were compared among the de novo patients of central serous chorioretinopathy (CSC), polypoidal choroidal vasculopathy (PCV) and the control.

Enrollment: 100 estimated patients

Sex: All

Ages: 20 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• CSC

  • neurosensory detachment in optical coherence tomography (OCT)
  • focal leakage in fluorescein angiography (FAG) and/or late choroidal hyperpermeability in indocyanine green angiography (ICGA)

• PCV

  • subretinal and/or sub-retinal pigment epithelial fluid in OCT
  • branching vascular network and/or polyps in ICGA

• Control

  • epiretinal membrane (ERM)
  • without underlying systemic, ophthalmic disease other than ERM

Exclusion criteria

• Previous history of using steroid (oral, topical)
• Previous history of CSC/PCV
• Previous history or evidence of intraocular inflammation including uveitis
• Co-existing retinal or choroidal diseases
• History of allergic reaction to fluorescein or indocyanine green dye
• Underlying systemic conditions that could affect the thrombotic profiles (e.g. diabetes, hypertension, metabolic syndrome, coronary artery disease, cerebrovascular diseases, stroke, chronic renal failure, current smoker, pregnancy, sleep disorder)

Trial design

100 participants in 3 patient groups

Central serous chorioretinopathy

Description:

De novo eligible CSC patients will be allocated in this group. Blood sampling, fluorescein angiography, indocyanine green angiography will be performed within a week after initial diagnosis.

Treatment:

Other: Blood sampling

Polypoidal choroidal vasculopathy

Description:

De novo eligible PCV patients will be allocated in this group. Blood sampling, fluorescein angiography, indocyanine green angiography will be performed within a week after initial diagnosis.

Treatment:

Other: Blood sampling

Epiretinal membrane

Description:

Idiopathic ERM patients will be allocated in this group. Blood sampling, fluorescein angiography, indocyanine green angiography will be performed within a week after initial diagnosis.

Treatment:

Other: Blood sampling